Innovent Reports First Patient Dosing in P-II Clinical Trial of Mazdutide for the Treatment of Obesity in Chinese Adults
Shots:
- The first patient has been dosed in the higher-dose cohort of a P-II trial to evaluate mazdutide vs PBO in a ratio (3:1) in 90 Chinese patients with overweight or obesity
- The trial met its 1EPs i.e., low-dose mazdutide showed a significant efficacy on body weight loss in a dose-dependent manner @24wk. & multiple cardio-metabolic benefits to patients were well tolerated and the overall safety profile was similar to other drugs
- In the P-Ib study, mazdutide titrated to 9mg had a good safety profile & a 12wk. body weight loss of 11.7%. The effectiveness & safety of mazdutide at a higher dose of 9.0mg will be further assessed by Innovent while patients with obesity will have a safer, more convenient & comparable therapy alternative with higher-dose mazdutide
Ref: PR Newswire | Image: Innovent
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.